Replimune Group (NASDAQ:REPL) Rating Lowered to Hold at Zacks Investment Research
According to Zacks, “Replimune Group, Inc. is a clinical-stage biotechnology company. It discovers, develops and commercializes oncolytic immunotherapy for the treatment of cancer diseases. The company’s product pipeline consists of RP1, RP2 & RP3 which are in clinical stage. Replimune Group, Inc. is based in MA, United States. “
Several other equities research analysts also recently issued reports on the stock. Chardan Capital reiterated a buy rating and set a $28.00 price objective on shares of Replimune Group in a research note on Thursday, August 15th. Wedbush started coverage on shares of Replimune Group in a research note on Wednesday, April 24th. They set an outperform rating and a $24.00 price objective for the company. JPMorgan Chase & Co. upgraded shares of Replimune Group from a neutral rating to an overweight rating and decreased their price objective for the stock from $27.00 to $26.00 in a research note on Friday, July 12th. ValuEngine upgraded shares of Replimune Group from a hold rating to a buy rating in a research note on Monday, August 12th. Finally, HC Wainwright started coverage on shares of Replimune Group in a research note on Monday, July 8th. They set a buy rating and a $26.00 price objective for the company. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. Replimune Group presently has a consensus rating of Buy and an average price target of $24.00.
Replimune Group (NASDAQ:REPL) last released its quarterly earnings data on Wednesday, August 14th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.32) by $0.02. On average, research analysts predict that Replimune Group will post -1.6 earnings per share for the current fiscal year.
Several hedge funds have recently made changes to their positions in the company. Northern Trust Corp boosted its stake in shares of Replimune Group by 1.2% in the second quarter. Northern Trust Corp now owns 123,931 shares of the company’s stock valued at $1,817,000 after purchasing an additional 1,437 shares during the period. BNP Paribas Arbitrage SA purchased a new position in shares of Replimune Group in the first quarter valued at $38,000. Emerald Mutual Fund Advisers Trust boosted its stake in shares of Replimune Group by 0.5% in the second quarter. Emerald Mutual Fund Advisers Trust now owns 711,770 shares of the company’s stock valued at $10,435,000 after purchasing an additional 3,650 shares during the period. Bank of New York Mellon Corp boosted its stake in shares of Replimune Group by 21.2% in the fourth quarter. Bank of New York Mellon Corp now owns 24,049 shares of the company’s stock valued at $240,000 after purchasing an additional 4,209 shares during the period. Finally, Geode Capital Management LLC boosted its stake in shares of Replimune Group by 15.0% in the fourth quarter. Geode Capital Management LLC now owns 52,687 shares of the company’s stock valued at $526,000 after purchasing an additional 6,878 shares during the period. Institutional investors and hedge funds own 59.80% of the company’s stock.
About Replimune Group
Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors.
Featured Story: How to identify percentage decliners
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Replimune Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Replimune Group and related companies with MarketBeat.com's FREE daily email newsletter.